TaiMed will be attending the 2023 Bio International Convention in Boston from June 5th to 8th. We invite you to visit our booth #1284 and explore collaborative opportunities in HIV-related assets and CDMO-related services.

With our extensive experience in monoclonal antibody (mAb) development and manufacturing, we have successfully developed and commercialized the mass-produced Trogarzo® (TMB-355), the first and only monoclonal antibody used for HIV treatment in the United States. Building upon this milestone, we are pleased to share that we are currently working on the development of the bispecific antibody combination TMB-365/TMB-380. This further underscores our commitment to advancing patient well-being.

We eagerly look forward to meeting you in Boston, where we can explore new possibilities, exchange insights, and pave the way for a healthier future together.

Back to the top